{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T14:07:39Z","timestamp":1768399659205,"version":"3.49.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2015,2,3]],"date-time":"2015-02-03T00:00:00Z","timestamp":1422921600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1007\/s40273-015-0260-4","type":"journal-article","created":{"date-parts":[[2015,2,2]],"date-time":"2015-02-02T11:19:05Z","timestamp":1422875945000},"page":"551-560","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["A Practical Guide for Using Registry Data to Inform Decisions About the Cost Effectiveness of New Cancer Drugs: Lessons Learned from the PHAROS Registry"],"prefix":"10.1007","volume":"33","author":[{"given":"Hedwig M.","family":"Blommestein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margreet G.","family":"Franken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carin A.","family":"Uyl-de Groot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,2,3]]},"reference":[{"key":"260_CR1","unstructured":"Gliklich R, Dreyer N, editors. Registries for evaluating patient outcomes: a user\u2019s guide (prepared by Outcome DEcIDE Center [Outcome Sciences, Inc. d\/b\/a Outcome] under Contract No. HHSA29020050035I TO2). AHRQ Publication No. 10-EHC049. 2nd ed. Rockville: Agency for Healthcare Research and Quality; 2010."},{"key":"260_CR2","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198529446.001.0001","volume-title":"Methods for the economic evaluation of health care programmes","author":"M Drummond","year":"2005","unstructured":"Drummond M, Sculpher M, Torrance G, O\u2019Brien B, Stoddart G. Methods for the economic evaluation of health care programmes. 3rd ed. New York: Oxford University Press Inc.; 2005.","edition":"3"},{"key":"260_CR3","unstructured":"Rutten-van M\u00f6lken MPMH, Uyl-de Groot C, Rutten F. Costs and effects: a guideline for economic evaluations in health care. 2nd ed. Amsterdam: Elsevier Gezondheidszorg; 2010."},{"issue":"2","key":"260_CR4","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jval.2013.02.002","volume":"16","author":"D Husereau","year":"2013","unstructured":"Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS): explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. Value Health. 2013;16(2):231\u201350.","journal-title":"Value Health"},{"issue":"2","key":"260_CR5","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jval.2013.12.011","volume":"17","author":"ML Berger","year":"2014","unstructured":"Berger ML, Martin BC, Husereau D, Worley K, Allen JD, Yang W, et al. A questionnaire to assess the relevance and credibility of observational studies to inform health care decision making: an ISPOR-AMCP-NPC Good Practice Task Force report. Value Health. 2014;17(2):143\u201356.","journal-title":"Value Health"},{"key":"260_CR6","doi-asserted-by":"crossref","unstructured":"Merlo G, Page K, Ratcliffe J, Halton K, Graves N. Bridging the gap: exploring the barriers to using economic evidence in healthcare decision making and strategies for improving uptake. Appl. Health Econ. Health Policy 2014. doi: 10.1007\/s40258-014-0132-7 .","DOI":"10.1007\/s40258-014-0132-7"},{"issue":"1","key":"260_CR7","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.healthpol.2006.03.006","volume":"80","author":"I Williams","year":"2007","unstructured":"Williams I, Bryan S. Understanding the limited impact of economic evaluation in health care resource allocation: a conceptual framework. Health Policy. 2007;80(1):135\u201343.","journal-title":"Health Policy"},{"issue":"7","key":"260_CR8","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1001\/jama.2009.1092","volume":"302","author":"NA Dreyer","year":"2009","unstructured":"Dreyer NA, Garner S. Registries for robust evidence. JAMA. 2009;302(7):790\u20131.","journal-title":"JAMA"},{"key":"260_CR9","unstructured":"Delwel GO. Guidance for outcomes research. 2008;270. Available at http:\/\/www.zorginstituutnederland.nl\/binaries\/content\/documents\/zinl-www\/documenten\/publicaties\/publications-in-english\/2008\/0812-guidance-for-outcomes-research\/0812-guidance-for-outcomes-research\/Guidance+for+Outcomes+Research.pdf ."},{"key":"260_CR10","unstructured":"Kuijpers MR, Toenders WGM. Assessment procedure for inpatient drugs [in Dutch: procedure beoordeling intramurale geneesmiddelen], Report no. 26022597. 2006."},{"key":"260_CR11","first-page":"321","volume":"7","author":"PC Huijgens","year":"2010","unstructured":"Huijgens PC, Posthuma EFM, Coebergh JWW, van de Poll-Franse LV, Uyl-de Groot CA, Sonneveld P. A \u2018population based registry\u2019 for hemato-oncology. Nederlands Tijdschrift voor Hematologie. 2010;7:321\u20135.","journal-title":"Nederlands Tijdschrift voor Hematologie"},{"issue":"5","key":"260_CR12","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/ejh.12264","volume":"92","author":"HM Blommestein","year":"2014","unstructured":"Blommestein HM, Issa DE, Pompen M, Ten Hoor G, Hogendoorn M, Joosten P, et al. Cost-effectiveness of rituximab as maintenance treatment for relapsed follicular lymphoma: results of a population-based study. Eur J Haematol. 2014;92(5):398\u2013406.","journal-title":"Eur J Haematol"},{"key":"260_CR13","unstructured":"van Gils CW, de Groot S, Tan SS, Redekop WK, Koopman M, Punt CJ, et al. Real-world resource use and costs of adjuvant treatment for stage III colon cancer. Eur J Cancer Care (Engl). 2013. doi: 10.11111\/ecc.12154 ."},{"key":"260_CR14","unstructured":"Health Insurance Board [in Dutch College Voor Zorgverzekeringen]. Guidelines for Pharmacoeconomic research, updated version. 2006;2014."},{"key":"260_CR15","doi-asserted-by":"crossref","unstructured":"van de Poll-Franse LV, Horevoorts N, Eenbergen Mv, Denollet J, Roukema JA, Aaronson NK, et al. The patient reported outcomes following initial treatment and long term evaluation of survivorship registry: scope, rationale and design of an infrastructure for the study of physical and psychosocial outcomes in cancer survivorship cohorts. Eur J Cancer. 2011;47(14):2188\u201394.","DOI":"10.1016\/j.ejca.2011.04.034"},{"issue":"6","key":"260_CR16","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1080\/02841860802120028","volume":"47","author":"F Kasteng","year":"2008","unstructured":"Kasteng F, Erlanson M, Hagberg H, Kimby E, Relander T, Lundkvist J. Cost-effectiveness of maintenance rituximab treatment after second line therapy in patients with follicular lymphoma in Sweden. Acta Oncol. 2008;47(6):1029\u201336.","journal-title":"Acta Oncol"},{"issue":"3","key":"260_CR17","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1093\/annonc\/mdm543","volume":"19","author":"R Pettengell","year":"2008","unstructured":"Pettengell R, Donatti C, Hoskin P, Poynton C, Kettle PJ, Hancock B, et al. The impact of follicular lymphoma on health-related quality of life. Ann Oncol. 2008;19(3):570\u20136.","journal-title":"Ann Oncol"},{"issue":"1","key":"260_CR18","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/jcpt.12020","volume":"38","author":"JG Gaultney","year":"2013","unstructured":"Gaultney JG, Franken MG, Tan SS, Redekop WK, Huijgens PC, Sonneveld P, et al. Real-world health care costs of relapsed\/refractory multiple myeloma during the era of novel cancer agents. J Clin Pharm Ther. 2013;38(1):41\u20137.","journal-title":"J Clin Pharm Ther"},{"issue":"1","key":"260_CR19","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejca.2012.06.010","volume":"49","author":"MG Franken","year":"2013","unstructured":"Franken MG, van Gils CW, Gaultney JG, Delwel GO, Goettsch W, Huijgens PC, et al. Practical feasibility of outcomes research in oncology: lessons learned in assessing drug use and cost-effectiveness in The Netherlands. Eur J Cancer. 2013;49(1):8\u201316.","journal-title":"Eur J Cancer"},{"issue":"2","key":"260_CR20","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jval.2013.12.009","volume":"17","author":"MG Franken","year":"2014","unstructured":"Franken MG, Gaultney JG, Blommestein HM, Huijgens PC, Sonneveld P, Redekop WK, et al. Policymaker, please consider your needs carefully: does outcomes research in relapsed or refractory multiple myeloma reduce policymaker uncertainty regarding value for money of bortezomib? Value Health. 2014;17(2):245\u201353.","journal-title":"Value Health"},{"issue":"2","key":"260_CR21","doi-asserted-by":"crossref","first-page":"131","DOI":"10.2165\/00019053-200826020-00004","volume":"26","author":"JE Stahl","year":"2008","unstructured":"Stahl JE. Modelling methods for pharmacoeconomics and health technology assessment: an overview and guide. Pharmacoeconomics. 2008;26(2):131\u201348.","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"260_CR22","doi-asserted-by":"crossref","first-page":"355","DOI":"10.2165\/00019053-200624040-00006","volume":"24","author":"Z Philips","year":"2006","unstructured":"Philips Z, Bojke L, Sculpher M, Claxton K, Golder S. Good practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality assessment. Pharmacoeconomics. 2006;24(4):355\u201371.","journal-title":"Pharmacoeconomics"},{"issue":"12 Suppl 1","key":"260_CR23","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.1016\/j.amjmed.2010.10.004","volume":"123","author":"J Concato","year":"2010","unstructured":"Concato J, Lawler EV, Lew RA, Gaziano JM, Aslan M, Huang GD. Observational methods in comparative effectiveness research. Am J Med. 2010;123(12 Suppl 1):e16\u201323.","journal-title":"Am J Med"},{"issue":"8","key":"260_CR24","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1111\/j.1524-4733.2009.00601.x","volume":"12","author":"E Cox","year":"2009","unstructured":"Cox E, Martin BC, Van Staa T, Garbe E, Siebert U, Johnson ML. Good research practices for comparative effectiveness research: approaches to mitigate bias and confounding in the design of nonrandomized studies of treatment effects using secondary data sources: the International Society for Pharmacoeconomics and Outcomes Research Good Research Practices for Retrospective Database Analysis Task Force Report: Part II. Value Health. 2009;12(8):1053\u201361.","journal-title":"Value Health"},{"issue":"8","key":"260_CR25","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1001\/jama.2010.1205","volume":"304","author":"BM Psaty","year":"2010","unstructured":"Psaty BM, Siscovick DS. Minimizing bias due to confounding by indication in comparative effectiveness research: the importance of restriction. JAMA. 2010;304(8):897\u20138.","journal-title":"JAMA"},{"issue":"5","key":"260_CR26","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.jclinepi.2005.07.004","volume":"59","author":"T Sturmer","year":"2006","unstructured":"Sturmer T, Joshi M, Glynn RJ, Avorn J, Rothman KJ, Schneeweiss S. A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods. J Clin Epidemiol. 2006;59(5):437\u201347.","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"260_CR27","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","volume":"70","author":"P Rosenbaum","year":"1983","unstructured":"Rosenbaum P, Rubin D. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70(1):41\u201355.","journal-title":"Biometrika"},{"issue":"3","key":"260_CR28","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1093\/aje\/kwj047","volume":"163","author":"T Kurth","year":"2006","unstructured":"Kurth T, Walker AM, Glynn RJ, Chan KA, Gaziano JM, Berger K, et al. Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of nonuniform effect. Am J Epidemiol. 2006;163(3):262\u201370.","journal-title":"Am J Epidemiol"},{"issue":"8","key":"260_CR29","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.jclinepi.2005.12.012","volume":"59","author":"RJ Glynn","year":"2006","unstructured":"Glynn RJ, Schneeweiss S, Wang PS, Levin R, Avorn J. Selective prescribing led to overestimation of the benefits of lipid-lowering drugs. J Clin Epidemiol. 2006;59(8):819\u201328.","journal-title":"J Clin Epidemiol"},{"issue":"8","key":"260_CR30","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s40273-013-0061-6","volume":"31","author":"CW Gils van","year":"2013","unstructured":"van Gils CW, de Groot S, Redekop WK, Koopman M, Punt CJ, Uyl-de Groot CA. Real-world cost-effectiveness of oxaliplatin in stage III colon cancer: a synthesis of clinical trial and daily practice evidence. Pharmacoeconomics. 2013;31(8):703\u201318.","journal-title":"Pharmacoeconomics"},{"key":"260_CR31","doi-asserted-by":"crossref","DOI":"10.1002\/9780470316696","volume-title":"Multiple imputation for nonresponse in surveys","author":"D Rubin","year":"1987","unstructured":"Rubin D. Multiple imputation for nonresponse in surveys. New York: Wiley; 1987."},{"key":"260_CR32","volume-title":"Statistical analysis with missing data","author":"R Little","year":"1987","unstructured":"Little R, Rubin D. Statistical analysis with missing data. New York: Wiley; 1987."},{"issue":"7","key":"260_CR33","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.zefq.2014.08.018","volume":"108","author":"A Gerber-Grote","year":"2014","unstructured":"Gerber-Grote A, Windeler J. What is the contribution of health economic evaluations to decision-making in health care? Experiences from 7 selected countries. Zeitschrift f\u00fcr Evidenz, Fortbildung und Qualit\u00e4t im Gesundheitswesen. 2014;108(7):358\u20139.","journal-title":"Zeitschrift f\u00fcr Evidenz, Fortbildung und Qualit\u00e4t im Gesundheitswesen"},{"issue":"7","key":"260_CR34","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.zefq.2014.06.016","volume":"108","author":"MG Franken","year":"2014","unstructured":"Franken MG, Koopmanschap M, Steenhoek A. Health economic evaluations in reimbursement decision making in the Netherlands; time to take it seriously? Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen. 2014;108(7):383\u20139.","journal-title":"Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen"},{"issue":"3","key":"260_CR35","doi-asserted-by":"crossref","first-page":"411","DOI":"10.2217\/pgs.10.187","volume":"12","author":"JG Gaultney","year":"2011","unstructured":"Gaultney JG, Sanhueza E, Janssen JJ, Redekop WK, Uyl-de Groot CA. Application of cost-effectiveness analysis to demonstrate the potential value of companion diagnostics in chronic myeloid leukemia. Pharmacogenomics. 2011;12(3):411\u201321.","journal-title":"Pharmacogenomics"},{"issue":"6","key":"260_CR36","first-page":"1673","volume":"271","author":"N Linden van der","year":"2014","unstructured":"van der Linden N, van Gils CW, Pescott CP, Buter J. Uyl-de Groot CA. Cetuximab in locally advanced squamous cell carcinoma of the head and neck: generalizability of EMR 062202-006 trial results. Eur Arch Otorhinolaryngol. 2014;271(6):1673\u20138.","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"12","key":"260_CR37","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1161\/CIRCULATIONAHA.107.703579","volume":"118","author":"BK Nallamothu","year":"2008","unstructured":"Nallamothu BK, Hayward RA, Bates ER. Beyond the randomized clinical trial: the role of effectiveness studies in evaluating cardiovascular therapies. Circulation. 2008;118(12):1294\u2013303.","journal-title":"Circulation"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40273-015-0260-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-015-0260-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-015-0260-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T23:23:22Z","timestamp":1717716202000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40273-015-0260-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,3]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["260"],"URL":"https:\/\/doi.org\/10.1007\/s40273-015-0260-4","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,3]]}}}